Jason’s Journey with ALK+ Metatstatic NSCLC

Opinion
Video

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

  • 34-year-old professional rock climber with ALK+ Stage IV metastatic NSCLC, previously healthy with no smoking history.
  • Persistent lower back pain unresponsive to rest and PT, followed by increased fatigue led to initial doctor visit.
  • CT scan revealed a left lung mass with lymph node involvement and a small metastasis on the spine; molecular testing confirmed ALK-positive status.
  • Started on lorlatinib, with manageable GI issues and fatigue as side effects; patient is motivated to return to climbing.
Recent Videos
5 experts in this video
5 experts in this video
Related Content
Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.

Immunotherapy/Radiation Shows Responses in NSCLC Brain Metastases

Russ Conroy
March 12th 2025
Article

Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

3 Things You Should Know About Managing ALK+ Metastatic NSCLC

3 Things You Should Know About Managing ALK+ Metastatic NSCLC

ONCOLOGY Staff
March 11th 2025
Article

Multidisciplinary approaches, RNA-based next-generation sequencing, and patient-specific front-line treatment decisions are all important for curating effective NSCLC treatments.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Ivonescimab Prolonged PFS vs Pembrolizumab in PD-L1+, Treatment-Naïve NSCLC

Ivonescimab Prolonged PFS vs Pembrolizumab in PD-L1+, Treatment-Naïve NSCLC

Tim Cortese
March 10th 2025
Article

Ivonescimab demonstrated a broad prolongation of PFS across various prespecified subgroups in patients with treatment-naïve, PD-L1–positive NSCLC.

Rezivertinib Improves PFS vs Gefitinib in EGFR-Mutant NSCLC

Rezivertinib Improves PFS vs Gefitinib in EGFR-Mutant NSCLC

Tim Cortese
March 8th 2025
Article

Results from the phase 3 REZOR trial show a median PFS of 19.3 months with rezivertinib vs 9.6 months with gefitinib in patients with NSCLC.